LYRAOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing implantable, office-based therapies for chronic rhinosinusitis (CRS), with LYR-210 as its main product candidate. The company is focused on turning ENT physician office procedures into a commercial treatment pathway, but it currently has no approved product sales and remains dependent on clinical progress and external financing.

Kysy yhtiöstä
Liikevaihto0,4milj. USD
−74,1 %v/v
Liikevoitto (EBIT)−31,0milj. USD
+67,8 %v/v
EBIT-marginaali−7 794,5%
−1 513,6 %-yks.v/v
Nettotulos−28,9milj. USD
+69,0 %v/v
Vapaa kassavirta−29,0milj. USD
+60,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−80−60−40−20020milj. USD2020: EBIT −22 milj. USD20202021: 0,29 milj. USD2021: EBIT −44 milj. USD20212022: 1,4 milj. USD2022: EBIT −56 milj. USD20222023: 1,6 milj. USD2023: EBIT −67 milj. USD20232024: 1,5 milj. USD2024: EBIT −96 milj. USD20242025: 0,40 milj. USD2025: EBIT −31 milj. USD20250,40−31
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Lyra Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
LYR-21090 %

Bioabsorbable implant designed for office-based delivery of therapy for chronic rhinosinusitis.

Collaboration and license revenue10 %

Revenue from licensing, development services, and clinical supply under partner agreements.

LYR-2200 %

Second product candidate in development for chronic rhinosinusitis-related use cases.

Asiakkaat

Lyra does not sell broadly to consumers; its commercial model depends on ENT physicians, patients with chronic rhinosinusitis, and ultimately payers that determine reimbursement. In the near term, the company’s economic buyers are clinical partners and licensees, while future demand for LYR-210 would come from physicians adopting an in-office procedure and insurers supporting coverage. Adoption hinges on physician willingness to change practice patterns and on patient acceptance of office-based treatment.

ENT physicians

They would administer the office-based placement procedure and must adopt the workflow for commercialization to succeed.

CRS patients

Patients with chronic rhinosinusitis are the end users; acceptance depends on tolerability and perceived benefit versus surgery.

Payers and reimbursement decision-makers

They determine whether the office procedure is covered and economically attractive versus endoscopic sinus surgery.

Strategic license partners

Regional partners such as LianBio fund and commercialize the product in licensed Asian territories.

Clinical investigators and trial sites

They support ongoing Phase 3 development and generate the data needed for regulatory review.

Strategia

The company’s near-term strategy is to preserve cash, continue the ENLIGHTEN 2 Phase 3 program for LYR-210, and evaluate strategic alternatives after the ENLIGHTEN 1 miss. Management is also seeking capital through equity, partnerships, and other financing options while restarting limited manufacturing to support potential future clinical supply needs. Longer term, success depends on proving clinical value, securing reimbursement, and rebuilding a commercial path for an office-based ENT procedure.

Continue LYR-210 clinical developmentLyhyt aikaväli

The company’s value depends on proving safety and efficacy after the ENLIGHTEN 1 setback.

Raise additional capitalLyhyt aikaväli

Lyra expects its current cash runway to extend only into the third quarter of 2026 and needs funding to continue operations.

Pursue strategic alternativesLyhyt aikaväli

After the failed primary endpoint in ENLIGHTEN 1, management is exploring transactions that could maximize shareholder value.

Rebuild a commercial pathwayKeskipitkä aikaväli

If LYR-210 is approved, adoption will require physician workflow change, reimbursement support, and manufacturing scale-up.

Maantiede

Lyra is headquartered in the United States and currently concentrates its development and corporate operations there. It has licensed LYR-210 rights in Greater China, South Korea, Singapore, and Thailand to LianBio, creating a regional commercialization footprint outside the U.S. If approved, future sales would likely be split between direct U.S. commercialization and partner-led international markets.

Riskit

Lyra is a high-risk development-stage company with substantial doubt about its ability to continue as a going concern, so financing risk is central to the story. Its lead program has already missed a key Phase 3 endpoint, and future value depends on clinical success, physician adoption, reimbursement, and manufacturing execution. As a result, regulatory, commercial, and operational setbacks could materially impair or eliminate future revenue potential.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Insufficient liquidity / going concern1Clinical trial failure2Market adoption and reimbursement3Manufacturing and personnel constraints4Competition5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Insufficient liquidity / going concernVaikutus: KriittinenTodennäköisyys: Korkea

    Management disclosed substantial doubt about continuing as a going concern and expects cash to fund operations only into Q3 2026.

    KohdistuuFunding needs for trialsManufacturingPublic-company costs
  2. Clinical trial failureVaikutus: KorkeaTodennäköisyys: Korkea

    LYR-210 failed the primary endpoint in ENLIGHTEN 1, which weakens the development case and commercialization path.

    Kohdistuu: LYR-210 Phase 3 program

  3. Market adoption and reimbursementVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Physicians may not adopt the office-based procedure and payers may not provide adequate coverage.

    Kohdistuu: ENT physician workflow and payer economics

  4. Manufacturing and personnel constraintsVaikutus: KeskitasoTodennäköisyys: Korkea

    The May 2024 reduction in force reduced experienced scientific and manufacturing staff, increasing execution risk.

    Kohdistuu: Clinical supply and scale-up readiness

  5. CompetitionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Approved and pipeline CRS therapies may offer better convenience, efficacy, or lower cost.

    Kohdistuu: Future product commercialization

Kysy Clarifolta: Lyra Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Collaboration revenue recognition

The LianBio agreement includes license, clinical supply, and development obligations recognized over time.

Vaikutus: Affects reported revenue timing and deferred revenue balances

Milestone constraint under ASC 606

Potential milestone payments are excluded from transaction price until sufficiently probable.

Vaikutus: Can delay revenue recognition even when the agreement has economic value

Going-concern assessment

Management states there is substantial doubt about continuing as a going concern.

Vaikutus: Influences liquidity disclosures and investor perception of solvency risk

Stock-based compensation and restructuring effects

The company has reduced headcount and continues to use equity compensation for key personnel.

Vaikutus: Affects operating expense levels and comparability across periods

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Gyre Therapeutics, Inc

GYRE · Pharmaceutical Preparations

Outlook Therapeutics, Inc.

OTLK · Biological Products, (No Diagnostic Substances)

Lisata Therapeutics, Inc

LSTA · Pharmaceutical Preparations

Lyell Immunopharma, Inc.

LYEL · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Lyra Therapeutics, Inc. (OTC) – Surgical & Medical Instruments & Apparat | Analyysi – Clarifo